Immune-inflamatory processes

Identification and characterisation of new immunomodulatory proteins and evaluation of their relevance and therapeutic potential in immune-mediated inflammatory diseases.
Analysis of new diagnostic/prognostic biomarkers in acute and chronic inflammatory pathologies.
Oxidative stress in epithelial cells of the respiratory pathways.
Inflammatory molecular mechanisms.
Molecular basis of urogenital diseases and male infertility. The immune response as a potential etiological factor of complex diseases.

• Gonzalez Munoz,S;Cervan Martin,M;Guzman Jimenez,A;Rodriguez Martin,AI;Garrido,N;Castilla,JA;Gonzalvo,MC et al, A genetic variant in the 3'-UTR of PIWIL4 confers risk for extreme phenotypes of male infertility by altering miR-215 and miR-136 binding affinity, Hum Reprod, 2025;40(9):1762-1772, doi:10.1093/humrep/deaf107
• González Muñoz,S;Long,Y;Guzmán Jiménez,A;Cerván Martín,M;Higueras Serrano,I;Castilla,JA;Clavero,A et al, Trans-ethnic GWAS meta-analysis of idiopathic spermatogenic failure highlights the immune-mediated nature of Sertoli cell-only syndrome., Commun Biol, 2025;8(1):571-571, doi:10.1038/s42003-025-08001-2
• Ferre Giraldo,A;Castells,M;Madurga,A;Arbiol Roca,A;de Rocco Ponce,M;Bassas,L;Vigues,F et al, Candidate Transcript Panel in Semen Extracellular Vesicles Can Improve Prediction of Aggressiveness of Prostate Cancer, Int. J. Mol. Sci., 2025;26(19):doi:10.3390/ijms26199562
• Checa,J;Fiol,P;Guevara,M;Aran,JM, TNFRSF1B Signaling Blockade Protects Airway Epithelial Cells from Oxidative Stress, Antioxidants, 2024;13(3):doi:10.3390/antiox13030368
• Ferre-Giraldo A, Castells M, Sánchez-Herrero JF, López-Rodrigo O, de Rocco-Ponce M, Bassas L, Vigués F, Sumoy L, Larriba S. Semen sEV tRF-based models increase non-invasive prediction accuracy of clinically significant prostate cancer among patients with moderately altered PSA levels. Int J Mol Sci. 2024 Sep 20;25(18):10122. doi: 10.3390/ijms251810122

• CI24-30620. Heptammune: a first-in-class biologic immunomodulator against autoimmune inflammatory bowel disease. FUNDACIÓ "LA CAIXA". Budget: 501.000€. 2024-2026. PI: JOSE MARIA ARAN PERRAMON.
• PI23/00285. Caracterización de Heptammune, un nuevo inmunomodulador biológico para controlar la hiperinflamación y la inmunidad entrenada desadaptada en enfermedades autoinmunes. Instituto de Salud Carlos III (ISCIII). Budget: 252.500€. 2024-2026. PI: JOSE MARIA ARAN PERRAMON.
• SLT036/24/000006. Desenvolupament i validació d'Heptammune, un innovador fàrmac biològic immunomodulador capaç de resoldre la inflamació en la malaltia inflamatòria intestinal. Generalitat de Catalunya. Budget: 199.892€. 2024-2026. PI: JOSE MARIA ARAN PERRAMON."
• PI20/00464. Caracterización, potencial diagnóstico y terapeútico de un nuevo inmunomodulador biológico para el tratamiento de enfermedades autoinmunes.. Instituto de Salud Carlos III (ISCIII). Budget: 171.820€. 2021-2025. PI: JOSE MARIA ARAN PERRAMON.

Active Patents:

• PAT10- ""Compositions and methods for immunomodulation""
  OWNERSHIP:100% IDIBELL
  REQUEST No.: EP11382240
  PRIORITY COUNTRY: European Union
  PRIORITY DATE: 15/07/11
  PCT APPLICATION: PCT/EP2012/063932 (16/07/12)
  IP: Josep Maria Aran
  Currently in national phases in Europe (Switzerland, Germany, Denmark, Spain, France, UK, Italy, Norway, Poland, Sweden, Turkey), Japan, USA, Australia and Canada.
  Patent granted in all these countries:"
• PAT62-COMPUESTOS BASADOS EN C4BP PARA EL TRATAMIENTO DE ENFERMEDADES INMUNOLÓGICAS
  EP17382187.7
  IP: J M Aran
  ownership: 100% IDIBELL
  06/07/2017
• PAT76- “Compounds for immunomodulation""
  INVENTORS: (by order of signature): Aran, J.M., Luque, A., Serrano, I.
  OWNERSHIP:100% IDIBELL
  REQUEST No.: EP19382910
  PRIORITY COUNTRY: European Union
  PRIORITY DATE: 17/10/19
• PAT090-Compounds for treating diseases
  INVENTORS: (by order of signature): Aran, J.M., Luque, A., Serrano, I.
  OWNERSHIP:100% IDIBELL
  PRIORITY COUNTRY: European Union
  PRIORITY DATE: 15/02/2024
  REQUEST: EP24382150.1